고객센터
찾아오시는길

HOME > 회원마당 > 보도자료보도자료

개의 줄기세포 소스; 지방, 골수, 난자

미래 | 2018.10.01 11:00 | 조회 4694
September 18, 2018

Preferred Sources for Isolating Stem Cells in Dogs

A recent article reviewed potential tissue sources and applications for stem cell use in veterinary patients.
By Natalie Stilwell, DVM, MS, PhD
stem cell therapyStem cell research has increased significantly in human medicine over the past 20 years, and stem cells derived from sites including bone marrow and adipose tissue are now widely used to treat various diseases. Comparatively, stem cell therapy has been explored minimally in veterinary medicine. Researchers at the Konkuk University’s Center for Stem Cell Research in South Korea recently provided a reviewof mesenchymal stem cell (MSC) therapy in animals.

RELATED: 

Mesenchymal Stem Cells

MSCs differ from hematopoietic stem cells in that they can differentiate into osteoblasts, adipocytes, cardiomyocytes, chondrocytes, hepatocytes, and stem cells. MSCs can be isolated from the following adult, neonatal, and fetal tissues:
  • Bone marrow
  • Adipose tissue
  • Heart
  • Peripheral blood
  • Dermis
  • Umbilical cord blood (UBC)
  • Placenta
  • Amniotic fluid

MSC implantation has been explored for the treatment of a variety of disorders in animals, including atopic dermatitis, osteoarthritis, chronic kidney disease, spinal cord injury, and skin wounds. According to the study authors, an important next step is to determine an ideal tissue source for high yield of MSCs.
 

Umbilical Cord Blood

Collection of MSCs from UCB has been explored primarily in humans, sheep, and horses. Relatively few studies have examined UCB-MSC use in pet animals, including dogs.

While collecting UCB is noninvasive and associated with low morbidity, this source yields significantly fewer MSCs compared with other tissues, such as bone marrow. Human studies showed that UCB-MSC isolation into cell culture media had a low estimated success rate of 26%, but the likelihood of successful isolation relied heavily on obtaining sufficient blood volume. Similarly, UCB-MSC yield in horses, goats, and sheep reportedly increases with increasing blood volume. While some canine studies have successfully isolated MSCs from UCB volumes as low as 8 mL, the authors of the current study reported an average yield of only 1 mL of UCB with a 66% success rate for MSC isolation. Thus, UCB may prove to be an unreliable source of stem cells in canine subjects.

Another important consideration is that UCB can only be obtained during C-section in the dog, as the bitch typically consumes the placenta and umbilical cord during natural birth. While 1 study reported higher MSC yields from fetal heart tissue, this method is more invasive and raises ethical concerns. Therefore, the authors stated that alternative options to neonatal and fetal tissues should be explored.
 

Adipose and Reproductive Tissues

Adipose tissue can also be used for MSC collection, as cells from this source can differentiate into adipogenic, osteogenic, and chrondrogenic types. Interestingly, reproductive tissues also yield high numbers of MSCs. Although ovaries and testes are frequently discarded as medical waste during sterilization, both tissues are “proven to be potent and reliable sources of MSCs,” according to the authors. Both also have the same multipotent potential as do adipose-derived MSCs. Therefore, the authors recommended future use of reproductive and adipose tissues, rather than UCB, for MSC collection in veterinary medicine.   

 
Dr. Stilwell received her DVM from Auburn University, followed by a MS in fisheries and aquatic sciences and a PhD in veterinary medical sciences from the University of Florida. She provides freelance medical writing and aquatic veterinary consulting services through her business, Seastar Communications and Consulting.

Sign up to receive the latest news in veterinary medicine.
보도자료
번호 제목 글쓴이 조회 날짜
101 텔로미어, 배아줄기세포 유전자도 제어 여섯시반 224 2019.08.23
100 DGIST, 위 점막 재생 줄기세포 존재 규명…위암 등 발병원인 규명·치.. 여섯시반 221 2019.08.22
99 인스코비 '줄기세포 활용 발모 촉진' 한·일 특허 취득 여섯시반 210 2019.08.21
98 첨바법 통과로 탄력받은 '줄기세포 치료제' 개발 여섯시반 224 2019.08.20
97 줄기세포 이식 후 생착률 높일 단서 찾았다 여섯시반 174 2019.08.19
96 ‘첨단바이오법’ 제약바이오산업 성장엔진 될까 Ss 28 2019.08.16
95 '줄기세포' 활용해 연골·조직 치료하는 시대 '눈앞' 여섯시반 230 2019.08.14
94 韓·美·日 기업 `줄기세포·재생의료` 국경 뛰어넘는 투자 ss 852 2019.07.01
93 1199건의 발의안 중 2건은 통과시켜야 한다고 합니다. 이희영 427 2018.10.05
92 병원내 배양 치료는 불법이 아닌데..우리보다 수준낮은 일본까지 가다니.... 미래 1011 2018.10.02
>> 개의 줄기세포 소스; 지방, 골수, 난자 미래 4695 2018.10.01
90 무상의료운동본부의 반발로 첨재법 통과 지연예상 미래 557 2018.10.01
89 첨단재생의료법 미래 689 2018.10.01
88 비급여진료비 연 2회 보고 의무화 추진 관리자 996 2017.09.26
87 [Medicine] '꿈의 신약' 유전자 치료제…국내시장 첫걸음 뗐다 관리자 2571 2017.08.28
86 당뇨병보다 두려운 ‘당뇨발’ … 줄기세포로 개선 도움 관리자 8217 2017.08.28
85 지방이식으로 만든 동안 얼굴, 오래 유지하는 노하우 ‘줄기세포’ 관리자 9328 2017.08.28
84 [핵잼 사이언스] 노화세포 ‘회춘’시켰다… 조로증 치료 희소식 관리자 1424 2017.08.10
83 안계훈 박사 ‘줄기세포-新재생의학’ 서적 출간 관리자 8484 2017.08.10
82 일 벤처기업, 만능줄기세포로 혈소판 대량생산…헌혈 없어도 외과수술 가능 관리자 7833 2017.08.10